Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label single-arm study of efgartigimod alfa in Chinese adults with generalized myasthenia gravis
CTR20240846Phase 4Active
- Sponsor
- argenx
- Start
- Apr 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Apr 2024; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20240846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240846.